Review



cd34 cd38 cell isolation kit  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Miltenyi Biotec cd34 cd38 cell isolation kit
    Cd34 Cd38 Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+cell+isolation/CD34%2BCD38-+Cell+Isolation+Kit%2C+human/pm41809821-64-12-18
    Average 95 stars, based on 3 article reviews
    cd34 cd38 cell isolation kit - by Bioz Stars, 2026-09
    95/100 stars

    Images

    Related Articles

    Cell Isolation:

    Article Title: Xeno-free generation of tissue-specific progenitor cells
    Article Snippet: .. For CD34+ cell isolation, trypsinized cells were sorted by CD34 microbead (Miltenyi Biotec, Auburn, Calif.) in the presence of Fc receptor blocker (Miltenyi Biotec, Auburn, Calif.) to block non-specific interaction. .. Real Time PCR Analysis RNA from progenitor cells enriched by magnetic bead separation was isolated with RNeasy mini kit (Qiagen, Valencia, Calif.) according to manufacturer's instructions.

    Article Title: Human intraepithelial mast cell differentiation and effector function are directed by TGF- β signaling
    Article Snippet: For RNA-Seq, buffy coats from consented donors were purchased from Research Blood Components, LLC. .. PB mononuclear cells were isolated using Ficoll paque density gradient centrifugation prior to CD34 + cell isolation using a CD34 MicroBead UltraPure Kit (Miltenyi Biotec) following the manufacturer’s protocol. .. Isolated cells were seeded at 150,000 cell/ml in StemSpan SFEM media (StemCell Technologies) containing SCF at 100 ng/ml, IL-6 at 50 ng/ml, IL-3 at 1 ng/ml for the first 3 weeks of culture (PeproTech), and penicillin/streptomycin at 1:100 (Invitrogen) (MC differentiation conditions).

    Article Title: Human intraepithelial mast cell differentiation and effector function are directed by TGF-β signaling
    Article Snippet: For RNA-Seq, buffy coats from consented donors were purchased from Research Blood Components, LLC. .. PB mononuclear cells were isolated using Ficoll paque density gradient centrifugation prior to CD34+ cell isolation using a CD34 MicroBead UltraPure Kit (Miltenyi Biotec) following the manufacturer’s protocol. .. Isolated cells were seeded at 150,000 cell/ml in StemSpan SFEM media (StemCell Technologies) contain- ing SCF at 100 ng/ml, IL-6 at 50 ng/ml, IL-3 at 1 ng/ml for the first 3 weeks of culture (PeproTech), and penicillin/streptomycin at 1:100 (Invitrogen) (MC differentiation conditions).

    Article Title: The 50 th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Poster Session (P001-P755).
    Article Snippet: S COLLECTION The 50 Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians – Poster Session (P001-P755) Bone Marrow Transplantation (2024) 59:140–665; https://doi.org/10.1038/s41409-024-02348-6 © Springer Nature Limited 2024 14 – 17 April, 2024 ● Hybrid Meeting Copyright: Modified and published with permission from https://www.ebmt.org/annual-meeting Sponsorship Statement: Publication of this supplement is sponsored by the European Society for Blood and Marrow Transplantation.. All content was reviewed and approved by the EBMT Committee, which held full responsibility for the abstract selections.

    Article Title: Circadian fluctuation of soluble CD26 dictates the impact of the timing of cord blood transplantation on acute graft-versus-host disease
    Article Snippet: The isolated CD3+ T cells were cultured in AIM-V medium (A3021002, Gibco) at a concentration of 2 × 105 cells/mL. .. For CD34+ cell isolation, immunomagnetic depletion was performed via CD34 microbeads (130-046-702, Miltenyi Biotech) following the recommended protocol. .. The isolated CD34+ cells were cultured in either StemSpan SFEM II medium (09655, STEMCELL Technologies) at 1 × 104 cells per milliliter or MethoCultTM H4435 enriched medium (04435, STEMCELL Technologies) at a density of 500 cells per well.

    Article Title: Non-viral DNA delivery and TALEN editing correct the sickle cell mutation in hematopoietic stem cells.
    Article Snippet: Diluted red blood cell suspension was then distributed into Sepmate tubes (StemCell #85450) containing 15mL of density gradient medium (StemCell, #07861). .. Tubes were centrifuged 10min at 12,000 × g, the supernatant was poured in a new 50mL tube, brought to a volume of 45mL with medium containing PBS, FBS, and EDTA, and centrifuged 7min at 300 × g. All pellets were pooled together to perform CD34+ cell isolation using CD34 progenitor kit according to the manufacturer’s recommendations (Miltenyi #130-046-703). .. HbSS CD34+ cells were cryopreserved in medium containing FBS and 10% DMSO (Sigma, #D2438) in liquid nitrogen.

    Article Title: Self-organization of sinusoidal vessels in pluripotent stem cell-derived human liver bud organoids.
    Article Snippet: The induction of tissue-specific vessels in in vitro living tissue systems remains challenging.. Here, we directly differentiated human pluripotent stem cells into CD32b putative liver sinusoidal progenitors by dictating developmental pathways.. By devising an inverted multilayered air–liquid interface culture, hepatic endoderm, septum mesenchyme, arterial and sinusoidal quadruple progenitors self-organize to generate and sustain hepatocyte-like cells neighboured by divergent endothelial subsets composed of CD32bCD31, LYVE1STAB1CD32bCD31THBDvWF and LYVE1THBDvWF cells.

    Article Title: Self-Organization of Sinusoidal Vessels in Pluripotent Stem Cell-derived Human Liver Bud Organoids
    Article Snippet: Antibodies and their dilution rates are as follows: anti-CD34 (BD Biosciences, 562577, 1:50), anti-CD32 (BioLegend, 303205, 1:50), anti-CD73 (Milteny Biotec, 130-095-183, 1:50), anti-CXCR4 (BioLegend, 306506, 1:50), anti-CD43 (BD Biosciences, 744662, 1:50), anti-CD31 (BD Biosciences, 740973, 1:50), anti-LYVE1 (R&D, AF2089, 1:50) conjugated to Alexa Fluor 647 by Lightning-Link (abcam), anti-EPCAM (BD Biosciences, 563180, 1:50), and anti-CD36 (BioLegend, 336207, 1:50). .. For CD34 + cell isolation, CD34 MicroBead Kit (Milteny Biotec, 130-046-702, 10 μl/10 million cells) was used. .. The data analyses were performed using the FlowJo software (Treestar).

    Blocking Assay:

    Article Title: Xeno-free generation of tissue-specific progenitor cells
    Article Snippet: .. For CD34+ cell isolation, trypsinized cells were sorted by CD34 microbead (Miltenyi Biotec, Auburn, Calif.) in the presence of Fc receptor blocker (Miltenyi Biotec, Auburn, Calif.) to block non-specific interaction. .. Real Time PCR Analysis RNA from progenitor cells enriched by magnetic bead separation was isolated with RNeasy mini kit (Qiagen, Valencia, Calif.) according to manufacturer's instructions.

    Isolation:

    Article Title: Human intraepithelial mast cell differentiation and effector function are directed by TGF- β signaling
    Article Snippet: For RNA-Seq, buffy coats from consented donors were purchased from Research Blood Components, LLC. .. PB mononuclear cells were isolated using Ficoll paque density gradient centrifugation prior to CD34 + cell isolation using a CD34 MicroBead UltraPure Kit (Miltenyi Biotec) following the manufacturer’s protocol. .. Isolated cells were seeded at 150,000 cell/ml in StemSpan SFEM media (StemCell Technologies) containing SCF at 100 ng/ml, IL-6 at 50 ng/ml, IL-3 at 1 ng/ml for the first 3 weeks of culture (PeproTech), and penicillin/streptomycin at 1:100 (Invitrogen) (MC differentiation conditions).

    Article Title: Human intraepithelial mast cell differentiation and effector function are directed by TGF-β signaling
    Article Snippet: For RNA-Seq, buffy coats from consented donors were purchased from Research Blood Components, LLC. .. PB mononuclear cells were isolated using Ficoll paque density gradient centrifugation prior to CD34+ cell isolation using a CD34 MicroBead UltraPure Kit (Miltenyi Biotec) following the manufacturer’s protocol. .. Isolated cells were seeded at 150,000 cell/ml in StemSpan SFEM media (StemCell Technologies) contain- ing SCF at 100 ng/ml, IL-6 at 50 ng/ml, IL-3 at 1 ng/ml for the first 3 weeks of culture (PeproTech), and penicillin/streptomycin at 1:100 (Invitrogen) (MC differentiation conditions).

    Gradient Centrifugation:

    Article Title: Human intraepithelial mast cell differentiation and effector function are directed by TGF- β signaling
    Article Snippet: For RNA-Seq, buffy coats from consented donors were purchased from Research Blood Components, LLC. .. PB mononuclear cells were isolated using Ficoll paque density gradient centrifugation prior to CD34 + cell isolation using a CD34 MicroBead UltraPure Kit (Miltenyi Biotec) following the manufacturer’s protocol. .. Isolated cells were seeded at 150,000 cell/ml in StemSpan SFEM media (StemCell Technologies) containing SCF at 100 ng/ml, IL-6 at 50 ng/ml, IL-3 at 1 ng/ml for the first 3 weeks of culture (PeproTech), and penicillin/streptomycin at 1:100 (Invitrogen) (MC differentiation conditions).

    Article Title: Human intraepithelial mast cell differentiation and effector function are directed by TGF-β signaling
    Article Snippet: For RNA-Seq, buffy coats from consented donors were purchased from Research Blood Components, LLC. .. PB mononuclear cells were isolated using Ficoll paque density gradient centrifugation prior to CD34+ cell isolation using a CD34 MicroBead UltraPure Kit (Miltenyi Biotec) following the manufacturer’s protocol. .. Isolated cells were seeded at 150,000 cell/ml in StemSpan SFEM media (StemCell Technologies) contain- ing SCF at 100 ng/ml, IL-6 at 50 ng/ml, IL-3 at 1 ng/ml for the first 3 weeks of culture (PeproTech), and penicillin/streptomycin at 1:100 (Invitrogen) (MC differentiation conditions).

    Magnetic Cell Separation:

    Article Title: The 50 th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Poster Session (P001-P755).
    Article Snippet: S COLLECTION The 50 Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians – Poster Session (P001-P755) Bone Marrow Transplantation (2024) 59:140–665; https://doi.org/10.1038/s41409-024-02348-6 © Springer Nature Limited 2024 14 – 17 April, 2024 ● Hybrid Meeting Copyright: Modified and published with permission from https://www.ebmt.org/annual-meeting Sponsorship Statement: Publication of this supplement is sponsored by the European Society for Blood and Marrow Transplantation.. All content was reviewed and approved by the EBMT Committee, which held full responsibility for the abstract selections.



    Similar Products

    95
    Miltenyi Biotec cd34 cd38 cell isolation kit
    Cd34 Cd38 Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+cell+isolation/CD34%2BCD38-+Cell+Isolation+Kit%2C+human/pm41809821-64-12-18
    Average 95 stars, based on 1 article reviews
    cd34 cd38 cell isolation kit - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    97
    Miltenyi Biotec cd34 cell isolation
    a Diagram of patients who underwent UCBT. Patients were divided into two groups on the basis of <t>stem</t> <t>cell</t> infusion timing, with a cutoff time of 9:40 am. UCBT, unrelated cord blood transplantation; CR, complete remission; MRD minimal residual disease; CB, cord blood. b Histogram showing the distribution of stem cell infusion times in the cohort. c , d Cumulative incidence (CI) of grade II-IV aGVHD ( c ) ( P = 0.416) and grade III-IV aGVHD ( d ) ( P = 0.004) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. The P values are two-sided and reported as exact values. e CI of overall chronic GVHD (cGVHD) in the earlier infusion (≤ 9:40 am) and later infusion (> 9:40 am) groups ( P = 0.276). The P values are two-sided and reported as exact values. f CI of 3-year TRM in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.067). The P values are two-sided and reported as exact values. g – i Probabilities of overall survival ( g ) ( P = 0.022), disease-free survival ( h ) ( P = 0.050), and GRFS ( i ) ( P < 0.001) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. j CI of 3-year relapse in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.775). The P values are two-sided and reported as exact values.The data were analyzed by Gray’s test ( c – f , and j ) and the log-rank test ( g – i ). Source data are provided as a Source Data file.
    Cd34 Cell Isolation, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+cell+isolation/CD34+MicroBead+Kit%2C+human/pmc12960979-313-1-12
    Average 97 stars, based on 1 article reviews
    cd34 cell isolation - by Bioz Stars, 2026-09
    97/100 stars
      Buy from Supplier

    97
    Miltenyi Biotec direct cd34 progenitor cell isolation kit
    a Diagram of patients who underwent UCBT. Patients were divided into two groups on the basis of <t>stem</t> <t>cell</t> infusion timing, with a cutoff time of 9:40 am. UCBT, unrelated cord blood transplantation; CR, complete remission; MRD minimal residual disease; CB, cord blood. b Histogram showing the distribution of stem cell infusion times in the cohort. c , d Cumulative incidence (CI) of grade II-IV aGVHD ( c ) ( P = 0.416) and grade III-IV aGVHD ( d ) ( P = 0.004) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. The P values are two-sided and reported as exact values. e CI of overall chronic GVHD (cGVHD) in the earlier infusion (≤ 9:40 am) and later infusion (> 9:40 am) groups ( P = 0.276). The P values are two-sided and reported as exact values. f CI of 3-year TRM in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.067). The P values are two-sided and reported as exact values. g – i Probabilities of overall survival ( g ) ( P = 0.022), disease-free survival ( h ) ( P = 0.050), and GRFS ( i ) ( P < 0.001) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. j CI of 3-year relapse in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.775). The P values are two-sided and reported as exact values.The data were analyzed by Gray’s test ( c – f , and j ) and the log-rank test ( g – i ). Source data are provided as a Source Data file.
    Direct Cd34 Progenitor Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+cell+isolation/CD34+MicroBead+Kit%2C+human/pm41288024-53-49-56
    Average 97 stars, based on 1 article reviews
    direct cd34 progenitor cell isolation kit - by Bioz Stars, 2026-09
    97/100 stars
      Buy from Supplier

    97
    Miltenyi Biotec human cd34 progenitor cell isolation kit
    a Diagram of patients who underwent UCBT. Patients were divided into two groups on the basis of <t>stem</t> <t>cell</t> infusion timing, with a cutoff time of 9:40 am. UCBT, unrelated cord blood transplantation; CR, complete remission; MRD minimal residual disease; CB, cord blood. b Histogram showing the distribution of stem cell infusion times in the cohort. c , d Cumulative incidence (CI) of grade II-IV aGVHD ( c ) ( P = 0.416) and grade III-IV aGVHD ( d ) ( P = 0.004) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. The P values are two-sided and reported as exact values. e CI of overall chronic GVHD (cGVHD) in the earlier infusion (≤ 9:40 am) and later infusion (> 9:40 am) groups ( P = 0.276). The P values are two-sided and reported as exact values. f CI of 3-year TRM in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.067). The P values are two-sided and reported as exact values. g – i Probabilities of overall survival ( g ) ( P = 0.022), disease-free survival ( h ) ( P = 0.050), and GRFS ( i ) ( P < 0.001) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. j CI of 3-year relapse in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.775). The P values are two-sided and reported as exact values.The data were analyzed by Gray’s test ( c – f , and j ) and the log-rank test ( g – i ). Source data are provided as a Source Data file.
    Human Cd34 Progenitor Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+cell+isolation/CD34+MicroBead+Kit%2C+human/pmc12628175__mmc3-354-29-35
    Average 97 stars, based on 1 article reviews
    human cd34 progenitor cell isolation kit - by Bioz Stars, 2026-09
    97/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec cd34 progenitor cell isolation kit
    a Diagram of patients who underwent UCBT. Patients were divided into two groups on the basis of <t>stem</t> <t>cell</t> infusion timing, with a cutoff time of 9:40 am. UCBT, unrelated cord blood transplantation; CR, complete remission; MRD minimal residual disease; CB, cord blood. b Histogram showing the distribution of stem cell infusion times in the cohort. c , d Cumulative incidence (CI) of grade II-IV aGVHD ( c ) ( P = 0.416) and grade III-IV aGVHD ( d ) ( P = 0.004) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. The P values are two-sided and reported as exact values. e CI of overall chronic GVHD (cGVHD) in the earlier infusion (≤ 9:40 am) and later infusion (> 9:40 am) groups ( P = 0.276). The P values are two-sided and reported as exact values. f CI of 3-year TRM in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.067). The P values are two-sided and reported as exact values. g – i Probabilities of overall survival ( g ) ( P = 0.022), disease-free survival ( h ) ( P = 0.050), and GRFS ( i ) ( P < 0.001) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. j CI of 3-year relapse in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.775). The P values are two-sided and reported as exact values.The data were analyzed by Gray’s test ( c – f , and j ) and the log-rank test ( g – i ). Source data are provided as a Source Data file.
    Cd34 Progenitor Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+cell+isolation/Diamond+CD34+Isolation+Kit%2C+human/us12453770-1672-33-38
    Average 94 stars, based on 1 article reviews
    cd34 progenitor cell isolation kit - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    97
    Miltenyi Biotec human cd34 microbeads kit miltenyi biotec
    a Diagram of patients who underwent UCBT. Patients were divided into two groups on the basis of <t>stem</t> <t>cell</t> infusion timing, with a cutoff time of 9:40 am. UCBT, unrelated cord blood transplantation; CR, complete remission; MRD minimal residual disease; CB, cord blood. b Histogram showing the distribution of stem cell infusion times in the cohort. c , d Cumulative incidence (CI) of grade II-IV aGVHD ( c ) ( P = 0.416) and grade III-IV aGVHD ( d ) ( P = 0.004) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. The P values are two-sided and reported as exact values. e CI of overall chronic GVHD (cGVHD) in the earlier infusion (≤ 9:40 am) and later infusion (> 9:40 am) groups ( P = 0.276). The P values are two-sided and reported as exact values. f CI of 3-year TRM in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.067). The P values are two-sided and reported as exact values. g – i Probabilities of overall survival ( g ) ( P = 0.022), disease-free survival ( h ) ( P = 0.050), and GRFS ( i ) ( P < 0.001) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. j CI of 3-year relapse in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.775). The P values are two-sided and reported as exact values.The data were analyzed by Gray’s test ( c – f , and j ) and the log-rank test ( g – i ). Source data are provided as a Source Data file.
    Human Cd34 Microbeads Kit Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+cell+isolation/NK+Cell+Isolation+Kit%2C+human/pm40803321-1327-105-109
    Average 97 stars, based on 1 article reviews
    human cd34 microbeads kit miltenyi biotec - by Bioz Stars, 2026-09
    97/100 stars
      Buy from Supplier

    Image Search Results


    a Diagram of patients who underwent UCBT. Patients were divided into two groups on the basis of stem cell infusion timing, with a cutoff time of 9:40 am. UCBT, unrelated cord blood transplantation; CR, complete remission; MRD minimal residual disease; CB, cord blood. b Histogram showing the distribution of stem cell infusion times in the cohort. c , d Cumulative incidence (CI) of grade II-IV aGVHD ( c ) ( P = 0.416) and grade III-IV aGVHD ( d ) ( P = 0.004) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. The P values are two-sided and reported as exact values. e CI of overall chronic GVHD (cGVHD) in the earlier infusion (≤ 9:40 am) and later infusion (> 9:40 am) groups ( P = 0.276). The P values are two-sided and reported as exact values. f CI of 3-year TRM in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.067). The P values are two-sided and reported as exact values. g – i Probabilities of overall survival ( g ) ( P = 0.022), disease-free survival ( h ) ( P = 0.050), and GRFS ( i ) ( P < 0.001) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. j CI of 3-year relapse in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.775). The P values are two-sided and reported as exact values.The data were analyzed by Gray’s test ( c – f , and j ) and the log-rank test ( g – i ). Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Circadian fluctuation of soluble CD26 dictates the impact of the timing of cord blood transplantation on acute graft-versus-host disease

    doi: 10.1038/s41467-026-68958-4

    Figure Lengend Snippet: a Diagram of patients who underwent UCBT. Patients were divided into two groups on the basis of stem cell infusion timing, with a cutoff time of 9:40 am. UCBT, unrelated cord blood transplantation; CR, complete remission; MRD minimal residual disease; CB, cord blood. b Histogram showing the distribution of stem cell infusion times in the cohort. c , d Cumulative incidence (CI) of grade II-IV aGVHD ( c ) ( P = 0.416) and grade III-IV aGVHD ( d ) ( P = 0.004) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. The P values are two-sided and reported as exact values. e CI of overall chronic GVHD (cGVHD) in the earlier infusion (≤ 9:40 am) and later infusion (> 9:40 am) groups ( P = 0.276). The P values are two-sided and reported as exact values. f CI of 3-year TRM in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.067). The P values are two-sided and reported as exact values. g – i Probabilities of overall survival ( g ) ( P = 0.022), disease-free survival ( h ) ( P = 0.050), and GRFS ( i ) ( P < 0.001) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. j CI of 3-year relapse in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.775). The P values are two-sided and reported as exact values.The data were analyzed by Gray’s test ( c – f , and j ) and the log-rank test ( g – i ). Source data are provided as a Source Data file.

    Article Snippet: For CD34+ cell isolation, immunomagnetic depletion was performed via CD34 microbeads (130-046-702, Miltenyi Biotech) following the recommended protocol.

    Techniques: Transplantation Assay